SecBot SecBot

JAZZ

Jazz Pharmaceuticals plc
Nasdaq· Pharmaceutical Preparations· Inc. L2· CIK 0001232524 Biotech & Drug Discovery
$213.26 −0.74 (−0.34%)
Oct 26 4:00 PM ET · prev $214.00
Market cap
$13.9B
Large cap
Consensus
Buy
93% Buy or better · 28 analysts
Median target
$300.00
+41% · range $225.00–337.00
Next earnings
Nov 2
in 7 days
1 year
+53.1%
from $139.33 · Oct 27
30 days
−10.5%
from $238.28
52-week range
$131.16–261.62
−18% from high · low Nov 7
Avg volume 20D
771.7K
shares / day
Short interest
5.48M
≈8.4% of shares · +17.2%
Days to cover
6.5
at average volume
Insider net
-$23.3M
0 buyers · 4 sellers · since Aug 5
New fund stakes
3
Q2 2026 13F · 2 exits
SecBot read MIXED 11 reports · 90 days
Balance 1 bearish · 2 bullish · 8 neutral oldest → newest, height = score
Avg score ·High conf. 9/11 ·Next Earnings date, Nov 2, 2026
Strongest BULLISH Jazz Pharmaceuticals completed the acquisition of Actio Biosciences for $820 million upfront, adding…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $23.3M.

  • InstitutionsBULLISH

    Q2 2026: 53 added (3 new), 31 trimmed or exited. Largest new: Norges Bank $158.3M, Woodline Partners $36.2M.

  • AnalystsBULLISH

    26 of 28 rate it Buy or better. Every target is above the price.

  • Short sellersBUILDING

    Short interest +17.2% to 5.48M shares. 6.5 days to cover, ≈8.4% of shares.

  • TrendDOWNTREND

    9% below its 50-day average.

Who's buying

13F· Q2 2026
3
new positions
2
exits
$207.3M
in new stakes
FundMoveSharesValue
FMR LLCDOUBLED4,609,326$1.1B
MILLENNIUM MANAGEMENT LLCTRIM763,880$184.1M
UBS Group AGDOUBLED756,865$182.4M
VICTORY CAPITAL MANAGEMENT INCDOUBLED686,719$165.5M
NORGES BANKNEW656,843$158.3M
Mariner, LLCDOUBLED608,615$146.6M
RENAISSANCE TECHNOLOGIES LLCTRIM562,073$135.4M
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLCDOUBLED436,893$105.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

28 analysts
Buy 93% rate it Buy or better
Strong Buy8Buy18Hold2Sell0Strong Sell0
12-month targets · 22 analysts

Price is below the lowest target. Median implies +41%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 21, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Oct 8, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Oct 7, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Sep 30, 2026Citigroup
INITIATE
INITIATEBuy
Sep 11, 2026UBS
MAINTAIN
MAINTAINBuy
Sep 10, 2026Barclays
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$23.3M
sold · 4 insiders
DateInsiderTypeValue
Oct 6, 2026
GALA RENEE D
President & CEO
SELL$472.8K
Oct 1, 2026
COZADD BRUCE C
Director
SELL$1.4M
Sep 10, 2026
Patil Neena M
EVP & Chief Legal Officer
SELL$289.1K
Sep 8, 2026
Henderson Mary Elizabeth
SVP, Technical Operations
TAX W/H$343.2K
Sep 8, 2026
Henderson Mary Elizabeth
SVP, Technical Operations
TAX W/H$3.6K
Sep 8, 2026
GALA RENEE D
President & CEO
SELL$486.1K
Sep 8, 2026
GALA RENEE D
President & CEO
TAX W/H$485.5K
Sep 1, 2026
COZADD BRUCE C
Director
SELL$1.5M

Earnings setup

Estimates
Nov 2
reports in 7 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
5,479,715
shares short
+17.2%
vs prior settlement
6.5
days to cover
≈8.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 SEC
Jazz Pharmaceuticals plc announced it will report its Q3 results on November 2, 2026.
PRESS-RELEASE — Impact 1/10
Oct 19, 2026 Earnings
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
DUBLIN, Oct. 19, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it wil
Oct 9, 2026 SEC
Jazz Pharmaceuticals disclosed that EVP and Chief Commercial Officer Samantha Pearce plans to retire, effective upon…
8-K — Impact 2/10
Oct 8, 2026 SEC
Director Anne O'Riordan filed a Form 144 notice of intent to sell 14,687 shares of Jazz Pharmaceuticals common stock…
144 — Impact 2/10
Oct 6, 2026 Insider
GALA RENEE D sold 2,000 shares
President & CEO @ $236.40 ($472.8K)
Oct 1, 2026 Insider
COZADD BRUCE C sold 6,000 shares
Director @ $230.33 ($1.4M)
Sep 10, 2026 Insider
Patil Neena M sold 1,200 shares
EVP & Chief Legal Officer @ $240.94 ($289.1K)
Sep 2, 2026 Event
HSR Early Termination: Jazz Pharmaceuticals Public Limited Company; Actio Biosciences, Inc.
The FTC granted early termination of the HSR Act waiting period for a transaction involving Jazz Pha
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 2, 2026
Earnings date
JAZZ Q3 2026 Earnings Scheduled — 2026-11-02
Recent
Oct 19, 2026
Earnings
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
DUBLIN, Oct. 19, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 third quarter financial…
Sep 24, 2026
Clinical Trial
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant
Phase 2 · COMPLETED
Sep 11, 2026
Clinical Trial
Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations
Phase 2 · COMPLETED
Sep 8, 2026
Clinical Trial
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
Phase 2 · COMPLETED
Sep 2, 2026
Enforcement
HSR Early Termination: Jazz Pharmaceuticals Public Limited Company; Actio Biosciences, Inc.
The FTC granted early termination of the HSR Act waiting period for a transaction involving Jazz Pharmaceuticals Public Limited Company; Actio Bioscie

SecBot reports

28 filings · 3 bullish · 2 bearish · 23 neutral
All JAZZ filing & press-release reports (28)